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Abstract
Background:  Most patients with growth hormone deficiency (GHD) show high body mass index.
Overweight subjects, but GHD patients, were demonstrated to have high left ventricular mass index
(LVMi) and abnormal LV geometric remodeling. We sought to study these characteristics in a group of
GHD patients, in an attempt to establish the BMI-independent role of GHD.
Methods: Fifty-four patients, 28 F and 26 M, aged 45.9 ± 13.1, with adult-onset GHD (pituitary adenomas
48.2%, empty sella 27.8%, pituitary inflammation 5.5%, cranio-pharyngioma 3.7%, not identified
pathogenesis 14.8%) were enrolled. To minimize any possible interferences of BMI on the aim of this study,
the control group included 20 age- and weight-matched healthy subjects. The LV geometry was identified
by the relationship between LVMi (cut-off 125 g/m2) and relative wall thickness (cut-off 0.45) at
echocardiography.
Results: There was no significant between-group difference in resting cardiac morphology and function,
nor when considering age-related discrepancy. The majority of patients had normal-low LVM/LVMi, but
about one fourth of them showed higher values. These findings correlated to relatively high circulating IGF-
1 and systolic blood pressure at rest. The main LV geometric pattern was eccentric hypertrophy in 22% of
GHD population (26% of with severe GHD) and in 15% of controls (p = NS).
Conclusion: Though the lack of significant differences in resting LV morphology and function, about 25%
of GHD patients showed high LVMi (consisting of eccentric hypertrophy), not dissimilarly to overweight
controls. This finding, which prognostic role is well known in obese and hypertensive patients, is worthy
to be investigated in GHD patients through wider controlled trials.
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Background
Growth hormone (GH) is essential for the regulation of
body composition, nutrient metabolism, extra-cellular
fluid volume, lean and fat mass, maintenance of muscle
mass and strength, myocardial structure and function [1-
5].
In the majority of the patients with adult-onset and/or
congenital growth hormone deficiency (GHD), previous
studies showed the presence of cardiac abnormalities,
mainly consistent with reduced left ventricular (LV) wall
thickness, myocardial hypotrophy, impaired LV perform-
ance at rest or exertion, often associated with obesity.
Some of these findings have been related to increased car-
diovascular risk [6-18].
However, there is only scant information about GHD
patients who have higher LV mass (LVM). Previous clini-
cal trials clearly demonstrated that in obese and hyperten-
sive patients with high LVM, increased relative risk for
cardiovascular events is related to abnormal LV geometric
remodeling [19-23].
Given that most GHD patients show high body mass
index (BMI), we managed to study the echocardiographic
characteristics of LVM and LV remodeling on this account.
In order to establish whether there is a BMI-independent
role of GHD on cardiac mass, the study group was com-
pared to an age- and weight-matched control group.
Methods
Study population
Fifty-four consecutive Caucasian patients, 28 women and
26 men, aged 45.9 ± 13.1 (range 19–67), with adult-onset
GHD were enrolled from January 2000 to May 2005. The
main diagnosis in these patients was pituitary adenomas
in 26 (48.2%), empty sella in 15 (27.8%), previous pitui-
tary inflammation in 3 (5.5%), cranio-pharyngioma in 2
(3.7%). The pathogenesis was not identified in 8 patients
(14.8%).
Isolated GHD was observed in 16 patients (29.6%). Of
the 31 patients with adenomas, inflammation or cranio-
pharyngioma, 25 had undergone surgery and 10 also
received radiotherapy.
The diagnosis of GHD was based on the decreased GH
responsiveness (GH-peak) to pyridostigmine + GH releas-
ing-hormone stimulation (oral administration of pyri-
dostigmine 120 mg, followed, after 60 minutes, by GH-
RH 100 ng/mL iv) and circulating IGF-I levels [24].
The GHD patients were divided into 2 groups based on
the response to test : GH-peak was < 3 ng/mL in 38
patients (group A, severe GHD), and 3 to 17 ng/mL in 16
(group B, mild GHD).
Circulating IGF-1 was also tested in the GHD population.
The normality range had been previously established in
our Institution as follows: a) 131–384 ng/mL in patients
aged 18 to 35, b) 100–312 ng/mL in those aged 36 to 50,
and c) 106–270 ng/mL in over 50s.
Free triiodothyronine (FT3) and thyroxine (FT4) were
measured in all the study population.
The onset of GHD (GHD length) was identified on the
basis of clinical history (first diagnosis of pituitary disease,
prior surgery, and, if any, previous chemical assays).
On admission, each patient underwent clinical evalua-
tion, including measurements of weight, height, body
mass index (BMI), sitting blood pressure, heart rate,
standard 12-lead electrocardiography and Doppler
echocardiography.
Acute coronary syndrome, previous myocardial infarc-
tion, congestive heart failure, congenital heart disease,
ventricular arrhythmias, asthma, cancer, severe renal and
hepatic dysfunction were all considered as exclusion crite-
ria.
The assessment of high blood pressure was carried out in
accordance with the current guidelines [25]. Patients who
showed mild-to-moderate hypertension were included in
the study. The final study group was compared to an age-
and weight-matched control group of 20 subjects with no
history of cardiac disease, from the same geographic
region.
Cardiac ultrasound
Transthoracic Doppler echocardiography was performed
with a commercial ultrasound unit equipped with 2.5–3.5
MHz transducers in harmonic imaging. Patients were
examined in the left lateral supine decubitus after 15 min-
utes resting by an experienced physician, and data stored
on magneto-optical disks.
Left ventricular end-diastolic/end-systolic diameters,
interventricular septum (IVS) and posterior wall (PW)
thickness, absolute and indexed LV mass (LVM and
LVMi), relative wall thickness (RWT = IVS + PW thickness/
LV end-diastolic diameter), endocardial and midwall frac-
tional shortening (EFS and MFS) were measured accord-
ing to recommendations of the American Society of
Echocardiography and other studies [21,22,26,27].
Based on the relationship between LVMi and RWT, using
the cut-off values of 125 g/m2 for LVMi and 0.45 for RWT,BMC Endocrine Disorders 2006, 6:1 http://www.biomedcentral.com/1472-6823/6/1
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both in men and women, the following geometric models
were identified: normal geometry, for RWT≤0.45 and
LVMi≤ 125 g/m2; concentric remodeling, for RWT>0.45 and
LVMi≤125 g/m2; eccentric hypertrophy, for RWT≤0.45 and
LVMi>125 g/m2; and concentric hypertrophy, for RWT>0.45
and LVMi>125 g/m2 [20-23].
The general distribution of LVM and LVMi in the GHD
population was also recognised, and 3 different categories
based on 2 median values were identified.
Once no wall motion abnormalities were found, LV ejec-
tion fraction was calculated by the single-plane Simpson
rule method (LV diastolic volume – LV systolic volume/LV
diastolic volume) from the 4-chamber apical view.
Diastolic function was evaluated by Doppler sampling at
LV inflow [trans-mitral valve blood flow sampling: early
(E) and late (A) peak velocity, E/A ratio, E-wave decelera-
tion time] and the upper right pulmonary vein outflow
[systolic (S) and diastolic (D) velocity, S/D ratio, and
reverse atrial velocity (Ap)], in accordance with the cur-
rent European guidelines [28].
Statistical analysis
Continuous variables are expressed as mean ± SD, except
for data expressed in percents (%). Exact Fisher test, anal-
ysis of variance with either Scheffé, Kruskal-Wallis, or chi-
squared test when appropriate, were used to check the
between-group differences.
Subjects' median age identified the age-related differences
in LVM and LV systolic/diastolic functional parameters,
and the differences were checked out by Student-T test.
Linear correlation between LVMi and IGF-I and GH-peak
was performed and a multivariate analysis was done in
order to establish the main determinants of LVMi in the
whole GHD population. The null hypothesis was rejected
at 2 tails for p < 0.05 (95% CI).
Results
Clinical features
Demographic and clinical characteristics of the study pop-
ulation are displayed in Table 1. With the exception of
GH-peak and circulating IGF-1 (both lower in group A
than in B, p < 0.0001 and < 0.05, respectively), there were
no significant differences in basal values.
A higher, but not significant, number of females was
present in group B (68.7%) than in A (39.5%) and C
(55%).
Growth hormone deficiency length was established from
8 to 384 months (mean value 154 ± 115 months).
At entry, some patients were already treated with specific
substitutive hormone for hypothyroidism (n = 29,
53.7%), hypogonadism (n = 26, 48.1%), hyposurrenal-
ism (n = 25, 46.3%) and diabetes insipidus (n = 5, 9.2%),
alone or in combination. Thus, FT3 and FT4 serum levels
were comparable among the 3 groups.
Cardiac morphology and function
Standard 12-lead ECG showed normal sinus rhythm in
each patient, with no evidence of significant arrhythmias
(atrial fibrillation, atrial flutter, premature ventricular
beats >100/h, non-sustained tachycardia) and/or ST-T
wave abnormalities suggestive of coronary artery disease.
Basal echocardiographic findings are displayed in Table 2.
The main difference regarded the higher prevalence of
extra-pericardial fat deposit in GHD patients than in con-
trols (p < 0.001).
Table 1: Demographic and clinical characteristics of the study population.
Severe GHD (n = 38) Mild GHD (n = 16) Controls (n = 20) p-value
Age 44.9 ± 14.0 48.2 ± 10.6 45.5 ± 12.0 NS
Gender (M/F) 23/15 3/11 9/11 NS
NYHA class 1.3 ± 0.5 1.1 ± 0.1 1.2 ± 0.1 NS
Body mass index 29.7 ± 6.8 31.4 ± 4.8 28.6 ± 4.4 NS
SBP (mmHg) 134.1 ± 16.1 133.6 ± 17.6 128.1 ± 10.3 NS
DBP (mmHg) 79.5 ± 10.8 81.8 ± 9.8 78.5 ± 11.1 NS
SBP > 135 and/or DBP > 85 mmHg 11 (28.4) 6 (37.5) 5 (25%) NS
GH-peak (ng/mL) 0.97 ± 0.84 8.31 ± 3.31 NA <0.0001
IGF-1 (ng/mL) 94.3 ± 64.6 130.5 ± 65.8 NA <0.05
FT3 (mmol/L) 4.2 ± 1.2 4.9 ± 1.6 5.3 ± 0.9 NS
FT4 (mmol/L) 12.9 ± 4.0 15.5 ± 3.8 14.2 ± 2.9 NS
Values are mean ± SD.
Legends: DBP, Diastolic Blood Pressure; GH, Growth Hormone; IGF-1, Insulin-Like Growth Factor; NA, Not Applicable; NYHA, New York Heart 
Association Functional Class; SBP, Systolic Blood Pressure; FT3, Free Triiodothyronine; FT4, Free Thyroxine.BMC Endocrine Disorders 2006, 6:1 http://www.biomedcentral.com/1472-6823/6/1
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Average values of LVM/LVMi were comparable among the
groups. Figure 1 also shows the median-related distribu-
tion of LVM and LVMi in 3 categories (LVM <168 g, 168–
244 g, >244 g, and LVMi <98 g/m2, 98–133 g/m2, >133 g/
m2) for each study group. More than 70% of patients with
severe GHD had LVM < 244 g and LVMi < 133 g/m2.
No significant age-related difference in LVMi, RWT, and
systolic functional parameters was observed within the
GHD group (Figure 2). Only a decrease in mitral E/A ratio
was consistent with age, the same as reported in the gen-
eral population [28].
Analysis of the LV geometric remodeling showed that the
majority of GHD patients and controls had "normal geom-
etry". Twelve GHD patients (10 with severe deficiency)
showed "eccentric hypertrophy" (22.2% vs 15.0% in con-
trols, NS). One patient from group A had "concentric
remodeling" and another from the same group had "con-
centric hypertrophy" (Figure 3).
Four out of the 12 GHD patients with "eccentric hypertro-
phy" (33.3%), the patient with "concentric remodeling" and
1/3 of controls with "eccentric hypertrophy" (33.3%) suf-
fered from systemic hypertension (NS).
However, in comparison with the GHD patients with low-
normal LVM/LVMi (n = 41), those with high cardiac mass
(n = 13) showed greater systolic blood pressure (131.7 ±
16.3 vs 118.2 ± 16.9 mmHg in the former group, respec-
tively; p = 0.02) and diastolic blood pressure (81.3 ± 7.1
vs 74.8 ± 11.0 mmHg, respectively; p = 0.06), measured
on admission.
Overall, there was a moderate, but significant, correlation
between LVMi and circulating IGF-I in the whole GHD
population (r 0.39, p < 0.005), and particularly in group
A (r 0.49, p < 0.002) (Figure 4). And IGF-1 was confirmed
to be the main determinant for LVMi at multivariate anal-
ysis (Table 3).
Table 3: Main determinants of LVMi in the GHD patient group at 
multivariate analysis.
Variable Regression (B) SE t-value p-value
Age 0.3090 0.3756 0.8229 0.416
GHD length 0.0056 0.0377 0.1485 0.883
GH-peak -0.4494 0.9574 0.4693 0.642
IGF-1 0.2646 0.0056 2.7553 0.009*
SBP 0.3869 0.3063 1.2633 0.214
Constant (C) = 29.193. Determinant coefficient (r squared) = 0.27.
Legends: GH, growth hormone; IGF-1, insulin-like growth factor; SE, 
standard error; SBP, systolic blood pressure.
Table 2: Resting echocardiographic measurements
Severe GHD (n = 38) Mild GHD (n = 16) Controls (n = 20) p-value
M-mode and two-dimensional parameters
LVEDD (mm) 49.4 ± 5.8 49.1 ± 4.0 49.3 ± 4.0 NS
LVESD (mm) 30.7 ± 4.5 29.4 ± 3.9 30.1 ± 3.5 NS
IVS (mm) 9.8 ± 1.8 10.6 ± 1.4 10.0 ± 1.5 NS
PW (mm) 7.8 ± 1.4 7.8 ± 1.3 8.4 ± 1.4 NS
RWT 0.36 ± 0.05 0.38 ± 0.05 0.38 ± 0.06 NS
LVM (g) 194.2 ± 62.6 197.8 ± 46.6 195.3 ± 44.5 NS
LVMi (g/m2) 104.8 ± 27.6 109.1 ± 24.9 106.1 ± 22.7 NS
LVDV (ml) 82.3 ± 20.7 77.2 ± 19.2 80.8 ± 15.5 NS
LVSV (ml) 30.4 ± 9.2 27.4 ± 8.3 31.7 ± 6.6 NS
LA systolic area (cm2) 16.8 ± 3.8 15.7 ± 2.5 16.7 ± 1.4 NS
RA systolic area (cm2) 14.2 ± 2.9 13.6 ± 2.2 14.1 ± 1.3 NS
Pericardial adiposity 26 (68.4%)* 10 (71.4%)* 4 (20%) <0.001
Left ventricular function
EFS (%) 39.0 ± 5.1 40.1 ± 5.5 38.8 ± 4.9 NS
MFS (%) 18.6 ± 2.7 18.8 ± 1.8 18.1 ± 2.3 NS
LVEF (%) 63.5 ± 5.8 63.6 ± 9.0 61.5 ± 5.3 NS
Mitral E/A velocity ratio 1.24 ± 0.56 0.99 ± 0.27 1.18 ± 0.48 NS
E-dt 175.5 ± 36.8 195.7 ± 53.2 173.7 ± 39.8 NS
PV S/D ratio 1.1 ± 0.6 1.0 ± 0.5 1.3 ± 0.3 NS
PV A velocity 28.9 ± 3.2 29.3 ± 5.2 27.3 ± 4.2 NS
Values are mean ± SD. Scheffé test for comparison of individual groups: *p < 0.01 (groups A-B vs C).
Legends: E/A, Early/late diastolic velocity at left ventricular (LV) inflow; E-dt, E-velocity deceleration time; EFS, Endocardial fractional shortening; IVS, 
Interventricular septal thickness; LA, Left atrium; LVDV, LV diastolic volume; LVEDD, LV end-systolic diameter; LVEF, LV ejection fraction; LVESD, LV 
end-systolic diameter; LVM/LVMi, absolute/indexed LV mass; LVSV, LV systolic volume; MFS, midwall fractional shortening; PV, Right superior 
pulmonary vein; PW, Posterior wall thickness; RA, Right atrium; RWT, Relative wall thickness; S/D, Systolic/Diastolic velocity.BMC Endocrine Disorders 2006, 6:1 http://www.biomedcentral.com/1472-6823/6/1
Page 5 of 8
(page number not for citation purposes)
Colour-flow mapping and Doppler sampling allowed
identification of trivial mitral valve regurgitation in 31
patients from group A (81.6%), 13 from group B (92.8%),
and 17 from group C (85%) (NS).
Discussion
The main findings from the present study indicate that
there is no significant difference in left ventricular mor-
phology and resting function between adult-onset GHD
patients and overweight healthy subjects.
As already demonstrated in other GHD populations,
about 75% of our patients had low or normal LVM/LVMi
[2-11]. Conversely, about a quarter of them had increased
values.
We know that high LVMi emerged as the most important
prognostic determinant for cardiovascular events in
patients with obesity and or hypertension [19-22,27,29].
While analysing the LV geometric remodeling, it was
established that LV concentric hypertrophy has 2.1–3.6
annual odds ratio, eccentric hypertrophy 1.0–2.9, and
concentric remodeling 0.3–2.4, for negative outcomes
[20-22,29].
Based on previous literature data on BMI in GHD patients,
we managed to evaluate whether the analysis of LV geo-
metric remodeling could improve the identification of
those subgroups at risk for cardiovascular events, in rela-
tion with the higher LVMi. To have found LV eccentric
hypertrophy in 22% of the cases (26% of with severe GHD)
likely implies that some patients are, from this point of
view, comparable to obese individuals, where this pattern
usually occurs in more than 20% of cases. Given the
specifc risk rate recognised in these latter category of
patients, we may assume that this minority of GHD
patients who show LV hypertrophy deserves further atten-
tion due to an equivalent estimated risk [19-22,29].
Age-related differences in left ventricular mass index (LVMi),  relative wall thickening (RWT), mitral E/A velocity ratio (E/A  ratio), left ventricular ejection fraction (LVEF), endocardial  fractional shortening (EFS), and midwall fractional shortening  (MFS), in the GHD population (n = 54) Figure 2
Age-related differences in left ventricular mass index (LVMi), 
relative wall thickening (RWT), mitral E/A velocity ratio (E/A 
ratio), left ventricular ejection fraction (LVEF), endocardial 
fractional shortening (EFS), and midwall fractional shortening 
(MFS), in the GHD population (n = 54).
Prevalence of left ventricular mass and left ventricular mass  index in the study population Figure 1
Prevalence of left ventricular mass and left ventricular mass 
index in the study population. LEGEND:m-GHD, patients 
with mild GHD; s-GHD, patients with severe GHD.BMC Endocrine Disorders 2006, 6:1 http://www.biomedcentral.com/1472-6823/6/1
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On the other hand, eccentric hypertrophy has been regarded
as an effective way to keep systolic function into normality
in obese patients, by resorting to the Starling reserve
[22,23]. This adaptive mechanism is likely to play a role
even in GHD patients, were we found no resting LV (systo-
lic and diastolic) dysfunction in comparison to controls.
Hence, our results are in agreement with Ozbey et al, who
demonstrated normal cardiac dimensions and LV systolic
function at rest in the majority of their GHD patients [30].
On the contrary, depressed systolic function at rest with
abnormal exertion response were recently shown by
Colao et al in about 79% of patients with severe GHD,
44% with mild GHD, and 6% of controls [31].
In our opinion, such conflicting results between previous
and present findings might be due to patients' age, length
of GHD and extent of pituitary disease, methods to assess
LV morphology and function, and local phenotypic char-
acteristics as well [32-35].
The main limitations of this study is the inadequate
patients' number to draw definite conclusions and the
lack of information about LV performance at exercise.
However, to evaluate the LV function was not a primary
end-point. In fact, cardiovascular function of GHD
patients, both at rest and/or exertion, can be affected by
several co-morbidities, as coronary artery disease (even
clinically silent), systemic hypertension, diabetes, meta-
bolic syndrome, lung disease, multiple endocrine dys-
function, which should be all adequately screened [31-
36].
Beyond greater circulating IGF-1, our patients with LV
hypertrophy also showed slight increase in blood pressure
at baseline, which pathophysiologic role on the modula-
tion of cardiac mass is well known [21].
The Paris prospective study, a large controlled trial where
the independent prognostic role of GH was investigated
in the general population, clearly demonstrated that car-
diovascular disorders mainly correlate to GH increase
Linear relationship between circulating IGF-1 and left ven- tricular mass index (LVMi) in patients with mild (open circles)  and severe (full circles) GHD Figure 4
Linear relationship between circulating IGF-1 and left ven-
tricular mass index (LVMi) in patients with mild (open circles) 
and severe (full circles) GHD. Correlation r-values and p-val-
ues in both groups and in patients with severe GHD are 
reported.
Scatter plot illustrating the left ventricular remodeling in  severe (open circles), partial (full circles) GHD and controls  (squares) Figure 3
Scatter plot illustrating the left ventricular remodeling in 
severe (open circles), partial (full circles) GHD and controls 
(squares). Numbers and percents (%) of the cases in each 
group are displayed in the table underneath. Legends: CR, 
concentric remodeling; CH, concentric hypertrophy; EH, 
eccentric hypertrophy; LVMi, left ventricular mass index; 
RWT, relative wall thickness.BMC Endocrine Disorders 2006, 6:1 http://www.biomedcentral.com/1472-6823/6/1
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rather than to deficiency [37]. Accordingly, it has been
unquestionably established that acromegalic patients are
at high risk for cardiovascular events, due to development
of LV hypertrophy, high blood pressure, and early vascu-
lar atherosclerosis [4,7,15,37-39].
Conclusion
Findings from the present study show that LV morphol-
ogy and resting function are not significantly different
between GHD patients and age- and weight-matched con-
trol subjects.
Overall, these patients had low-normal LVM and LVMi,
and high prevalence of pericardial fat deposit. However,
in about 22% of them (26% of with severe GHD) an
increase in LVMi, similar to overweight controls, can be
observed. The main geometric pattern consists of LV
eccentric hypertrophy.
In this series, LVMi was found to correlate with relatively
high circulating IGF-1, but not to GH-peak or GHD
length, and with resting systolic blood pressure.
Therefore, the analysis of the LV geometric remodeling
appears to be such a simple echocardiographic method
that can help physicians to better identify which category
of GHD patients is likely to be at risk for cardiovascular
events, strictly due to changes in cardiac mass.
Further study is needed to validate our results and estab-
lish their actual prognostic impact.
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